Page last updated: 2024-10-29

ketamine and Colorectal Neoplasms

ketamine has been researched along with Colorectal Neoplasms in 6 studies

Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.

Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.

Research Excerpts

ExcerptRelevanceReference
" Ninety-two patients undergoing laparoscopic radical resection of colorectal cancer were randomly assigned to either the esketamine (K group) or non-eskatamine (C group) group."9.69Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. ( Ai, Y; He, L; Liu, S; Xu, Y; Zhang, C, 2023)
"This study aimed at examining the effect of a single sub-anesthetic dose of ketamine on postoperative fatigue syndrome (POFS) in patients undergoing radical laparoscopic surgery for colorectal cancer (CRC)."9.51Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study. ( Cheng, H; Zhang, H; Zhao, L, 2022)
"Intraoperative low-dose ketamine administration did not convey any favourable impacts on overall postoperative NK cell activity, inflammatory responses, and prognosis in colorectal cancer surgery patients."9.41The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. ( Cho, JS; Jun, JH; Kim, NY; Kwak, YL; Lee, S; Shim, JK, 2021)
" Ninety-two patients undergoing laparoscopic radical resection of colorectal cancer were randomly assigned to either the esketamine (K group) or non-eskatamine (C group) group."5.69Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial. ( Ai, Y; He, L; Liu, S; Xu, Y; Zhang, C, 2023)
"Ketamine treatment inhibited colon cancer cell viability and migration in HT29 and SW480 cells."5.56Ketamine inhibits aerobic glycolysis in colorectal cancer cells by blocking the NMDA receptor-CaMK II-c-Myc pathway. ( Duan, W; Hu, J; Liu, Y, 2020)
"This study aimed at examining the effect of a single sub-anesthetic dose of ketamine on postoperative fatigue syndrome (POFS) in patients undergoing radical laparoscopic surgery for colorectal cancer (CRC)."5.51Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study. ( Cheng, H; Zhang, H; Zhao, L, 2022)
"Intraoperative low-dose ketamine administration did not convey any favourable impacts on overall postoperative NK cell activity, inflammatory responses, and prognosis in colorectal cancer surgery patients."5.41The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial. ( Cho, JS; Jun, JH; Kim, NY; Kwak, YL; Lee, S; Shim, JK, 2021)
"Ketamine treatment inhibited colon cancer cell viability and migration in HT29 and SW480 cells."1.56Ketamine inhibits aerobic glycolysis in colorectal cancer cells by blocking the NMDA receptor-CaMK II-c-Myc pathway. ( Duan, W; Hu, J; Liu, Y, 2020)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's4 (66.67)2.80

Authors

AuthorsStudies
Zhao, L1
Zhang, H1
Cheng, H1
Xu, Y1
He, L1
Liu, S1
Zhang, C1
Ai, Y1
Hu, J2
Duan, W2
Liu, Y2
Cho, JS1
Kim, NY1
Shim, JK1
Jun, JH1
Lee, S1
Kwak, YL1
Blaj, C1
Bringmann, A1
Schmidt, EM1
Urbischek, M1
Lamprecht, S1
Fröhlich, T1
Arnold, GJ1
Krebs, S1
Blum, H1
Hermeking, H1
Jung, A1
Kirchner, T1
Horst, D1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection[NCT03273231]100 participants (Anticipated)Interventional2017-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

3 trials available for ketamine and Colorectal Neoplasms

ArticleYear
Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study.
    Journal of affective disorders, 2022, 09-01, Volume: 312

    Topics: Anesthetics; Colorectal Neoplasms; Double-Blind Method; Fatigue; Humans; Interleukin-6; Ketamine; La

2022
Intraoperative intravenous low-dose esketamine improves quality of early recovery after laparoscopic radical resection of colorectal cancer: A prospective, randomized controlled trial.
    PloS one, 2023, Volume: 18, Issue:6

    Topics: Colorectal Neoplasms; Double-Blind Method; Humans; Ketamine; Laparoscopy; Pain, Postoperative; Prosp

2023
The immunomodulatory effect of ketamine in colorectal cancer surgery: a randomized-controlled trial.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2021, Volume: 68, Issue:5

    Topics: Colorectal Neoplasms; Double-Blind Method; Humans; Immunomodulation; Interleukin-6; Ketamine; Tumor

2021

Other Studies

3 other studies available for ketamine and Colorectal Neoplasms

ArticleYear
Ketamine inhibits aerobic glycolysis in colorectal cancer cells by blocking the NMDA receptor-CaMK II-c-Myc pathway.
    Clinical and experimental pharmacology & physiology, 2020, Volume: 47, Issue:5

    Topics: Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Movement; C

2020
Ketamine inhibits colorectal cancer cells malignant potential via blockage of NMDA receptor.
    Experimental and molecular pathology, 2019, Volume: 107

    Topics: Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Excitatory Amino Acid Antagonists; Humans; Ke

2019
ADNP Is a Therapeutically Inducible Repressor of WNT Signaling in Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jun-01, Volume: 23, Issue:11

    Topics: Animals; Biomarkers, Tumor; Cell Proliferation; Colorectal Neoplasms; Female; Gene Expression Regula

2017